Durvalumab

Durvalumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Intrahepatic Cholangiocarcinoma、Endometrial Cancer、Epithelial Ovarian Cancer、Non-small Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Durvalumab 研究

• Histotripsy in Biliary Tract Cancer

  不适用招募中美国NCT07853690

• Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

  I 期 / II 期招募中South KoreaNCT06911255

• Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

  II 期招募中美国NCT04992780

• Single cEll pRofiling PErsistaNce To ImmuNothErapy

  II 期招募中西班牙NCT06680739

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  II 期招募中美国NCT01042379

• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

  II 期招募中美国NCT05068232

• Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

  不适用招募中西班牙NCT06634199

• Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

  I 期 / II 期招募中South KoreaNCT03694236

• JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

  不适用招募中法国NCT04294771

• Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

  II 期招募中中国台湾NCT06999694

• Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

  II 期招募中美国NCT05253131

• Imjudo & Imfinzi PMS

  不适用招募中South KoreaNCT06544629

• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

  II 期招募中英国NCT03740893

• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

  II 期招募中美国NCT07459634

• Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

  I 期招募中美国NCT06564623

• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

  II 期招募中美国NCT07603856

• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

  I 期 / II 期招募中比利时荷兰西班牙NCT04954599

• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

  II 期招募中德国NCT06223711

• CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

  I 期 / II 期招募中美国NCT06548412

• WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

  II 期招募中德国NCT04644289

• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  I 期 / II 期招募中美国NCT03539822

• SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

  II 期招募中中国NCT07174947

• Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

  II 期招募中德国NCT06810609

• A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

  I 期 / II 期招募中法国NCT06508216

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。